Neoadjuvant Lazertinib Therapy in EGFR-Mutation Positive Lung Adenocarcinoma Detected by BALF Liquid Biopsy

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 19, 2022

Primary Completion Date

May 19, 2024

Study Completion Date

May 19, 2027

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG

Neoadjuvant lazertinib

Lazertinib 240mg p.o once daily.

Trial Locations (1)

RECRUITING

Konkuk University Medical Center, Seoul

All Listed Sponsors

collaborator

Yuhan Corporation

INDUSTRY

lead

Konkuk University Medical Center

OTHER